

PHARMACEUTICAL BUSINESS GROUP (INDIA) LIMITED

CIN: U24239MH1991PLC059995

Registered Office: 11/12 Udyog Nagar, S.V. Road, Goregaon West, Mumbai 400 104.

Tel: 022- 67607080 E-Mail- pbgil.250191@gmail.com/ gtblmumbai@gtbl.in

21st July, 2026

Corporate Relationship Department

BSE Limited

Floor 25, Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001

Scrip Code – 530199

corp.relations@bseindia.com

Listing Department

National Stock Exchange of India Limited

Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai- 400051

Symbol: THEMISMED

takeover@nse.co.in

Gujarat Themis Biosyn Limited

Block No. 69-c, GIDC Industrial Estate,
Vapi – 396195, Gujarat.
cfoassist@themismedicare.com

Dear Sir / Madam,

Sub: Disclosure under Regulation 31 of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 – Indirect Incumbrancer.

With reference to the captioned subject, we enclose herewith the disclosure Pursuant to Regulation 31 / applicable provisions of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 in respect of the creation of:

- a) a pledge over 25,24,245 equity shares, constituting 51% of the issued and paid-up share capital of Pharmaceutical Business Group (India) Limited ("PBGIL"); and
- b) a non-disposal undertaking over 21,57,855 equity shares, constituting 47.98% of the issued and paid-up share capital of PBGIL;

by Vividhmargi Investments Private Limited (VIPL) in favour of CTL Trusteeship Limited, acting as Debenture Trustee, pursuant to the Pledge Agreement-cum-Non-Disposal Undertaking dated June 28, 2026, executed in connection with the Debenture Trust Deed dated June 25, 2026.

As PBGIL holds 5,12,40,000 equity shares, constituting 47.02% of the equity share capital of Gujarat Themis Biosyn Limited (GTBL or Target), the aforesaid creation of pledge and non-disposal undertaking over the shares of PBGIL would result in an indirect encumbrance over 5,12,40,000 equity shares of the GTBL held by PBGIL. PBGIL is part of promoter group entity.

PHARMACEUTICAL BUSINESS GROUP (INDIA) LIMITED

CIN: U24239MH1991PLC059995

Registered Office: 11/12 Udyog Nagar, S.V. Road, Goregaon West, Mumbai 400 104.

Tel: 022- 67607080 E-Mail- pbgil.250191@gmail.com/ gtblmumbai@gtbl.in

This is for your information and record please.

Thanking you,

Yours faithfully,

For **Pharmaceutical Business Group (India) Limited**

Mrs. Jayshree D. Patel
Director

Encl.: As above

PHARMACEUTICAL BUSINESS GROUP (INDIA) LIMITED

CIN: U24239MH1991PLC059995

Registered Office: 11/12 Udyog Nagar, S.V. Road, Goregaon West, Mumbai 400 104.

Tel: 022- 67607080 E-Mail- pbgil.250191@gmail.com/ gtblmumbai@gtbl.in

Reg 31(1) – creation of encumbrances / pledge by promoters (file with SE and TC, by Promoters – within 7 working days from encumbrance)

Disclosure by the Promoter(s) to the stock exchanges and to the Target Company for encumbrance of shares / invocation of encumbrance/ release of encumbrance, in terms of Regulation 31(1) and 31(2) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Creation of encumbrance:

1	Name of the Target Company (TC)	Gujarat Themis Biosyn Limited
2	Names of the stock exchanges where the shares of the target company are listed	BSE Limited and National Stock Exchange of India Limited
3	Date of reporting	3 rd July, 2026
4	Name of the promoter or PAC on whose shares encumbrance has been created /released/ invoked	Indirect encumbrance on Shares in GTBL held by Pharmaceutical Business Group (India) Limited, as explained in Note below.
5	Details of the creation of encumbrance:	As mentioned below

Sr.	Name of promoter (s) or PACs with him	Promoter holding in the target company (1)		Promoter holding already encumbered (2)	
		Number	% of total	Number	% of total
(1)	(2)	(3)	(4)	(5)	(6)
1	Pharmaceutical Business Group (India) Limited (PBGIL)*	5,12,40,000	47.02	25,50,000	4.98

PHARMACEUTICAL BUSINESS GROUP (INDIA) LIMITED

CIN: U24239MH1991PLC059995

Registered Office: 11/12 Udyog Nagar, S.V. Road, Goregaon West, Mumbai 400 104.

Tel: 022- 67607080 E-Mail- pbgil.250191@gmail.com/ gtblmumbai@gtbl.in

Sr.	Details of events pertaining to encumbrance (3)							Post event holding of encumbered shares \$ (Creation)	
	Type of event (creation / release / invocation)	Date of creation/ release/ invocation of encumbrance	Type of encumbrance (pledge/ lien/ non disposal undertaking/ others)	Reasons for encumbrance **	Number	% of share capital	Name of the entity in whose favor shares encumbered ***	Number	% of total
(7)	(8)	(9)	(10)	(11)	(12)	(13)	(14)	(15)	(16)
1	Creation	29/06/2026	Indirect encumbrance	As stated below	5,12,40,000	47.02	CTL Trusteeship Limited Lender: Kotak Credit Opportunities Fund Trust	5,12,40,000	47.02

Release of encumbrance:

1	Name of the Target Company (TC)	Gujarat Themis Biosyn Limited
2	Names of the stock exchanges where the shares of the target company are listed	BSE Limited and National Stock Exchange of India Limited
3	Date of reporting	16 th July, 2026
4	Name of the promoter or PAC on whose shares encumbrance has been created /released/ invoked	Indirect encumbrance on Shares in GTBL held by Pharmaceutical Business Group (India) Limited, as explained in Note below.
5	Details of the creation of encumbrance:	As mentioned below

Sr.	Name of promoter (s) or PACs with him	Promoter holding in the target company (1)		Promoter holding already encumbered (2)	
		Number	% of total	Number	% of total
(1)	(2)	(3)	(4)	(5)	(6)
1	Pharmaceutical Business Group (India) Limited (PBGIL)*	5,12,40,000	47.02%	5,12,40,000 (Indirect encumbrance) 25,50,000 (Pledge)	100% 2.34%

PHARMACEUTICAL BUSINESS GROUP (INDIA) LIMITED

CIN: U24239MH1991PLC059995

Registered Office: 11/12 Udyog Nagar, S.V. Road, Goregaon West, Mumbai 400 104.

Tel: 022- 67607080 E-Mail- pbgil.250191@gmail.com/ gtblmumbai@gtbl.in

Sr.	Details of events pertaining to encumbrance (3)							Post event holding of encumbered shares \$ (Creation)	
	Type of event (creation / release / invocation)	Date of creation/ release/ invocation of encumbrance	Type of encumbrance (pledge/ lien/ non disposal undertaking/ others)	Reasons for encumbrance **	Number	% of share capital	Name of the entity in whose favor shares encumbered ***	Number	% of total
(7)	(8)	(9)	(10)	(11)	(12)	(13)	(14)	(15)	(16)
1	Release	08/07/2026	Pledge	Repayment of Loan	25,45,000 (Pledge)	2.33%	CTL Trusteeship Limited Lender: Kotak Credit Opportunities Fund Trust	5,12,40,000 (Indirect encumbrance) 5,000 (Pledge)	100% 0.004%

Indirect encumbrance arising pursuant to (i) pledge over 25,24,245 equity shares and (ii) non-disposal undertaking over 21,57,855 equity shares of Pharmaceutical Business Group (India) Limited.

The shareholding represents only Direct pledged shareholding. Indirect encumbrance is not covered in Post event holding of encumbered shares. Therefore the indirect holding of 5,12,40,000 is same before and after pledge release transaction.

This disclosure is being made keeping in view indirect encumbrance on shares of the Target. Pharmaceutical Business Group (India) Limited (PBGIL) holds 5,12,40,000 equity shares, constituting 47.02% of the equity share capital of Gujarat Themis Biosyn Limited (GTBL or Target). Vividhmargi Investment Private Limited (VIPL) has created encumbrance on its holding by way of; (i) pledge over 25,24,245 equity shares in PBGIL, and (ii) non-disposal undertaking over 21,57,855 equity shares in PBGIL. Accordingly, said encumbrance on the shares in PBGIL would result in indirect encumbrance on equity shares in GTBL held by PBGIL.

Pursuant to the Debenture Trust Deed and the Pledge Agreement-cum-Non-Disposal Undertaking.

\$\{creation [(2)+(3)] / release [(2)-(3)]/ invocation [(1)-(3)]\}\$

(**) The names of all the promoters, their shareholding in the target company and their pledged shareholding as on the reporting date should appear in the table irrespective of whether they are reporting on the date of event or not.

PHARMACEUTICAL BUSINESS GROUP (INDIA) LIMITED

CIN: U24239MH1991PLC059995

Registered Office: 11/12 Udyog Nagar, S.V. Road, Goregaon West, Mumbai 400 104.

Tel: 022- 67607080 E-Mail- pbgil.250191@gmail.com/ gtblmumbai@gtbl.in

(*) Total share capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement. Diluted share / voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities / warrants into equity shares of the TC.

Yours faithfully,

For **Pharmaceutical Business Group (India) Limited**

Mrs. Jayshree D. Patel
Director

PHARMACEUTICAL BUSINESS GROUP (INDIA) LIMITED

CIN: U24239MH1991PLC059995

Registered Office: 11/12 Udyog Nagar, S.V. Road, Goregaon West, Mumbai 400 104.

Tel: 022- 67607080 E-Mail- pbgil.250191@gmail.com/ gtblmumbai@gtbl.in

Format for disclosure of reasons for encumbrance

1	Name of listed company	Gujarat Themis Biosyn Limited
2	Name of the recognised stock exchanges where the shares of the company are listed	BSE Limited and National Stock Exchange of India Limited
3	Name of the promoter(s) / PACs whose shares have been encumbered	Pharmaceutical Business Group (India) Limited
4	Total promoter shareholding in the listed company	No. of Shares: 7,72,18,083
5	Encumbered shares as a % of promoter shareholding	66.36%
6	Whether encumbered share is 50% or more of promoter shareholding	Yes
7	Whether encumbered share is 20% or more of total share capital	Yes

Details of all the existing events/ agreements pertaining to encumbrance

Type of encumbrance (pledge, lien, negative lien, non-disposal undertaking etc. or any other covenant, transaction, condition or arrangement in the nature of encumbrance)		Indirect encumbrance over 5,12,40,000 equity shares of Gujarat Themis Biosyn Limited arising pursuant to (i) pledge over 25,24,245 equity shares and (ii) non-disposal undertaking over 21,57,855 equity shares of Pharmaceutical Business Group (India) Limited created by Vividhmargi Investments Private Limited in favour of CTL Trusteeship Limited under the Pledge Agreement-cum-Non-Disposal Undertaking.	
No. and % of shares encumbered		No. of shares: 5,12,40,000 % of total share capital: 47.02%.	
Specific details about the Encumbrance	Name of the entity in whose favour shares encumbered (X)	CTL Trusteeship Limited (acting as Debenture Trustee) for holder of the Debentures. Lender: Kotak Credit Opportunities Fund Trust	
	Whether the entity X is a scheduled commercial bank, public financial institution, NBFC or housing finance company? If No, provide the nature of the business of the entity.	No. CTL Trusteeship Limited is engaged in the business of providing Debenture Trustee and Security Trustee services.	
	Names of all other entities in the agreement	Listed company and its group companies (if any)	Vividhmargi Investments Private Limited, Pharmaceutical Business Group (India) Limited and CTL Trusteeship Limited
	Whether the encumbrance is relating to any debt instruments viz. debenture,	YES / NO If yes,	Yes, Debentures

PHARMACEUTICAL BUSINESS GROUP (INDIA) LIMITED

CIN: U24239MH1991PLC059995

Registered Office: 11/12 Udyog Nagar, S.V. Road, Goregaon West, Mumbai 400 104.

Tel: 022- 67607080 E-Mail- pbgil.250191@gmail.com/ gtblmumbai@gtbl.in

	commercial paper, certificate of deposit etc.? If yes, provide details about the instrument, including credit rating	1. Name of the issuer	OSS Software Solutions Labs Private Limited
		2. Details of the debt instrument	Unrated, Unlisted, Secured, Redeemable Non-Convertible Debentures
		3. Whether the debt instrument is listed on stock exchanges?	No
		4. Credit Rating of the debt instrument	Not Applicable
		5. ISIN of the instrument	Not yet allotted
Security Cover / Asset Cover	Value of shares on the date of event / agreement (A)		Rs. 19,68,89,70,000 (5,12,40,000 Equity Shares* 384.25)
	Amount involved (against which shares have been encumbered) (B)		Rs. 135,00,00,000
	Ratio of A / B		1:14.58
End use of money	Borrowed amount to be utilized for what purpose – (a) Personal use by promoters and PACs (b) For the benefit of listed company Provide details including amount, purpose of raising money by listed company, schedule for utilization of amount, repayment schedule etc. (a) Any other reason (please specify)		Personal use by promoters and PACs